Basic considerations on treatment of increased platelet aggregation in diabetic vasculopathic patients.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use*; D001791:Blood Platelet Disorders / Q000188:drug therapy / Q000209:etiology*; D003925:Diabetic Angiopathies / Q000097:blood / Q000150:complications*; D004176:Dipyridamole / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D010208:Papaverine / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects
D000893:Anti-Inflammatory Agents; D000244:Adenosine Diphosphate; D004176:Dipyridamole; D010208:Papaverine; D001241:Aspirin